Does active treatment of rheumatoid arthritis limit disease-associated bone loss?

Size: px
Start display at page:

Download "Does active treatment of rheumatoid arthritis limit disease-associated bone loss?"

Transcription

1 Rheumatology 2002;41: Does active treatment of rheumatoid arthritis limit disease-associated bone loss? A. L. Dolan, C. Moniz 1, H. Abraha 1 and P. Pitt 2 Department of Rheumatology, Queen Elizabeth Hospital, London SE18, 1 Department of Clinical Biochemistry, Kings College Hospital, London SE5 and 2 Department of Rheumatology, Bromley Hospital, Kent, UK Abstract Objective. Generalized bone loss in rheumatoid arthritis (RA) is multi-factorial, with the inflammatory disease itself thought to contribute to bone loss. To study the extent to which control of disease activity affects bone turnover in RA and whether treatment with diseasemodifying anti-rheumatic drugs (DMARDs) reduces bone turnover and loss of bone mass, we measured bone density and biochemical markers of bone resorption in a group of patients with active RA starting on DMARDS. Methods. Patients with active RA were enrolled on starting a new DMARD. Patients were mobile and none took steroids or any treatment for osteoporosis. Clinical and laboratory measures of disease activity were made at 3-monthly intervals and an index of disease activity (DAS) calculated. Bone density was assessed at 0, 1 and 2 yr (Hologic QDR 4500c). Urinary deoxypyridinoline (D-PYR) and pyridinoline (PYR) were measured by ELISA at 0, 3, 6, 9 and 12 months. Results. Forty patients were enrolled, mean age 59.5 (range 31 76), 26 female, 14 male, 25 had established RA, 15 had RA for <2 yr. Baseline D-PYR was elevated (8.4"4.55 nmolummol creatinine) and correlated with ESR (r=0.6, P<0.01) and DAS (r=0.4, P<0.05). On treatment ESR and DAS fell by 38.5 and 29.3%, respectively. D-PYR was reduced by 12.3% by 9 months (P<0.01). Spearman rank order correlation showed ESR to be the most significant determinant of D-PYR over 1 yr (r=0.43, P<0.001). Serial bone density was available on 21 patients. There was no significant change in BMD over the 2 yr. The change in DAS over 0 3 months showed an inverse relationship with the percent change in spine over 1 yr (r=20.5, P=0.05). The change in D-PYR over 0 3 months was not closely related to the change in BMD at hip or spine at 1 yr. Conclusion. Disease activity is a significant determinant of bone turnover in RA. Bone resorption markers fall on treatment of RA with DMARDs and no change in BMD was demonstrated at 2 yr. This study suggests the need to control disease activity in RA in order to prevent systemic bone loss. KEY WORDS: Rheumatoid arthritis, Inflammation, Osteoporosis, Bone turnover, Bone markers. Rheumatoid arthritis (RA) is associated with a high prevalence of bone loss resulting in juxta-articular and generalized osteoporosis w1, 2x. Generalized bone loss may be influenced by immobility, the inflammatory process and treatments such as steroids, whilst juxtaarticular loss is probably due to local release of inflammatory agents such as cytokines from the rheumatoid synovium and articular immobility w1x. The consequence is osteoporotic fractures of hip, vertebrae and peripheral bones w3x resulting in considerable cost in both acute orthopaedic management, rehabilitation and increased dependence. Submitted 2 April 2001; revised version accepted 25 March Correspondence to: A. L. Dolan, Department of Rheumatology, Queen Elizabeth Hospital, Stadium Road, London SE18 4QH, UK. Current practice is to introduce treatment early in RA. UK guidelines recommend the use of diseasemodifying anti-rheumatic drugs (DMARDs) to reduce inflammatory synovitis and control disease progression w4x. In early RA intervention, using DMARD, has been shown to improve functional outcome and retard bone loss. Emery w5x suggests that bone density assessment using dual energy X-ray absorption (DEXA) scans provides an outcome measure for assessing the consequences of active disease and the response to treatment. However, these measurements are expensive and not widely available, necessitating referral elsewhere and patient inconvenience. It is now possible to assess bone turnover using a range of biochemical markers to reflect bone resorption and formation w6x. Pyridinoline (PYR) and 1047 ß 2002 British Society for Rheumatology

2 1048 A. L. Dolan et al. deoxypyridinoline (D-PYR) assess collagen breakdown. These cross-links form between the two collagen fibrils and on breakdown of collagen are released unchanged in the urine. PYR is the main cross-link between type II collagen fibres in cartilage and although PYR is also the most abundant cross-link in bone, D-PYR is bone specific being derived only from type 1 collagen. D-PYR has been validated as a useful marker for bone resorption and is elevated in high turnover states such as Paget s and post-menopausal osteoporosis w6x. Crosssectional studies have shown resorption markers to be elevated in active RA w7 9x. PYR levels correlated with other cartilage markers and with ESR, suggesting levels reflect joint damage and joint inflammation. D-PYR from bone also correlated with disease activity and may thus reflect diffuse bone loss. Gough w10x found PYR elevation to correlate with other markers of disease activity and bone density loss at the femoral neck. Biochemical markers may thus provide an alternative indication of change in bone turnover in response to treatment. Previous studies of bone markers in RA have been cross-sectional and in small numbers w7, 8x. Such studies do not allow assessment of whether markers provide an indication of the ability of DMARD treatment to alter bone turnover. This prospective study design considers a homogeneous group of RA patients, with active disease and known clinical characteristics, as they start conventional monotherapy for RA, without the confounding factors of immobility or steroid use, to assess the effect of disease control on bone markers and density. Our aim was to evaluate whether bone turnover markers could be used at earlier time points in the treatment to evaluate on-going bone loss and hence potential loss of BMD in the future. Methods Patients Forty patients who fulfilled the ACR criteria for RA were enrolled. Patients were assessed by a single investigator at three District General Hospitals in South East London, after approval of the protocol by local medical Ethical Committees. Formal consent was obtained in all patients. Patients with established RA were identified at the time the treating clinician felt disease activity merited change to a new DMARD, and patients with early disease enrolled at the time they started DMARDs for the first time. All patients had active disease demonstrated by three out of six or more tender joints, three or more swollen joints, 45 min morning stiffness and ESR >25 mmhg. Patients with physical incapacity (Steinbrocker III and IV) were excluded from the study. Other exclusion criteria were previous or present treatment with steroids or other treatment known to affect bone metabolism, such as bisphosphonates or calcium and vitamin D, or a concurrent disease which might affect bone metabolism. Peri-menopausal females within 5 yr of menopause were excluded, as this is a time of rapid change in bone turnover. No patients were taking HRT. At baseline patients were commenced on a DMARD considered appropriate by the treating physician. Seventeen were put on methotrexate, 10 on gold, 13 on sulphasalazine. Assessment Disease activity was assessed at 0, 3, 6, 12, 18 and 24 months by a visual analogue scale for pain on a 100 mm scale (VAS pain), patient s global assessment as a visual analogue score, early morning stiffness and Health Assessment Questionnaire (HAQ). A 28-point joint count was performed for number of tender and swollen joints. A disease activity score (DAS 28) w11x was calculated. Full blood count, ESR and liver function were measured at the assessments and as required by DMARD monitoring protocols. Imaging BMD of the spine and hip was assessed using a dual energy X-ray absorptiometer on a Hologic QDR 4500c at 0, 12 and 24 months. Results are expressed in gucm 2 and Z-scores. The long-term precision on this scanner over 7 yr was 1.12% for PA spine BMD and 2.21% for femoral neck BMD w12x. The results were compared with a normal database that had previously been shown not to differ from a south-east England population. As this study was conducted in the context of a service clinic, for logistical reasons, not all patients attended for three serial scans. Biochemical markers All patients had fasting second morning urine and blood samples taken before starting DMARDs and at 3, 6, 9, 12, 18 and 24 months. D-PYR and PYR cross-links were measured using ELISA assays. Results were expressed in nmolummol creatinine. Intra- and interassay coefficients of variation were less than 7 and 10%, respectively. Statistical analysis Results are expressed as mean and standard deviation. BMD and bone marker results were shown to be normally distributed by the Kolmogorov Smirnov test and were thus compared with baseline values using paired Student s t-tests. Continuous variables were compared by Pearson s correlation coefficient. The pre-determined analysis was to examine the relationship of disease activity (ESR, DAS, HAQ, VAS pain, patient assessment) with bone turnover markers at baseline and to explore the effect on these factors of a single intervention, i.e. treatment. The effect of early change in markers was related to BMD change at 1 yr to see if markers could be used to predict subsequent bone change in a clinical setting. A power calculation suggested 83% power to show change in BMD greater than the error of the measure.

3 Bone turnover in treated RA 1049 TABLE 1. Change in disease markers with treatment Months D-PYR (nmolummol creatinine) (S.D.) 8.4 (4.5) 7.24 (3.4) 7.2 (3.8) a 6.83 (2.5) b 7.36 (3.3) PYR (nmolummol creatinine) (S.D.) 56.4 (64) (43) (33) 37.6 (30) 34.2 (20) a DAS 5.5 (1.12) 4.66 (1.2) b 4.33 (1.3) b 3.38 (1.2) b 3.89 (1) b Early morning stiffness (86.3) 55.0 (66.7) c 43.5 (64.2) c (75.2) c 29 (42.2) c HAQ (12.2) 9.08 (5.8) 8.69 (6) b 7.48 (6.1) b 7.47 (5.6) a VAS pain 51.4 (19.3) 39.4 (20) c 35.2 (24.3) c 33.7 (23) b (20.2) c Patient global assessment 54.8 (21.5) (22) b 34.8 (23.7) c 36.6 (24.6) a 33.5 (25) a ESR (mmhg) 43.6 (27) 30.3 (19) a 25.5 (25) a 24.9 (18) b 26.8 (18) b a P<0.05; b P<0.01; c P<0.001 with respect to baseline. Results Forty patients were enrolled, mean age 59.9 (range 31 76), 26 females, 24 male. Twenty-five had established RA, 15 had RA for <2 yr and had not previously used a DMARD. Changes in measures of disease activity and bone markers are shown in Table 1. Mean baseline ESR was 43.6"27.4 mmhg, mean baseline DAS 5.5"1.1. As expected, baseline DAS was closely correlated with ESR (r=0.67, P<0.0001), since DAS includes ESR. As a result of treatment of the active RA with DMARDs both ESR and DAS fell and at 1 yr mean ESR was 26.8"18 mmhg and DAS 3.89"1, (P<0.01) (Table 1). HAQ improved significantly by 6 months and patients reported significant improvement in pain (VAS), early morning stiffness and patient assessment by 3 months, demonstrating the efficacy of the DMARD treatment. Bone markers Serial bone marker results were available on 40 patients. Baseline D-PYR was elevated (8.4"4.55 nmolummol creatinine) in the RA patient group compared with normal age- and sex-matched controls (4.91"1.1) P< D-PYR was significantly reduced by 6 months, 7.2"3.8 nmolummol creatinine (P<0.05), and at 9 months, 6.83"2.5 nmolummol creatinine (P<0.01), with respect to baseline values. At baseline, D-PYR levels correlated with ESR (r=0.6, P<0.001) and with DAS (r=0.4, P<0.05). HAQ, reflecting functional state, showed no relationship with bone resorption over time (r=0.007). Spearman rank order correlation showed ESR to be the most significant determinant of bone resorption (D-PYR) over 1 yr (r=0.43, P<0.001). PYR levels were raised at baseline and fell over 1 yr, but not by a significant degree (Table 1). Baseline PYR and D-PYR were only weakly correlated (r=0.64), reflecting their different sites of origin and a discordant TABLE 2. Change in BMD with treatment Months DEXA spine 0.98 (0.16) 0.97 (0.2) 0.97 (0.19) DEXA NOF 0.79 (0.16) 0.79 (0.16) ( 0.16) a P<0.05, b P<0.01, c P<0.001 with respect to baseline. effect of disease on bone and cartilage. The relationship of PYR to ESR was not significant (r=0.26). Imaging Serial bone density data was available on 21 patients (Table 2). There were eight patients with early rheumatoid and 13 patients with RA for longer than 2 yr prior to the study, who had DEXA scans. There was no difference in sub-analyses of these groups and therefore in view of the small numbers the data was analysed as a whole. At baseline, the spine Z-score for the group was ("1.57) and the neck of femur Z-score ("1.35). Overall, there was no significant change in BMD at either site over the 2-yr follow-up (Table 2). Eleven out of 21 patients showed an increase in spine BMD from baseline by 1 yr. There was an inverse relationship between the change in DAS over 0 3 months and the percent change in spine over 1 yr (r=20.52, P=0.05). There was no relationship between D-PYR at baseline and change in spine or hip BMD by 1 or 2 yr. The change in D-PYR over 0 3 months was not closely linked to the change in BMD at hip (r=20.25) or spine (r=20.36) at 1 yr, so this cannot be a useful predictor of bone mass in RA over short time periods. Discussion Long-term observational studies have been pessimistic as to the outcome of treatment in RA, suggesting that DMARDs fail to limit erosive damage and do not prevent consequent functional disability w13x. Such results are quoted as the reason for adopting aggressive combination therapies w14, 15x. However, these long-term studies inevitably reflect a time when DMARDs were not traditionally introduced until erosions were present and before the early use of drugs such as methotrexate. More recent studies have shown that currently used DMARDs such as methotrexate and leflunomide w16x can inhibit erosions within a short time, both in early and established disease. As such, the future outcome for RA may be more optimistic. Our study shows no change in bone mineral density in hip or spine over 2 yr of active treatment, suggesting that current monotherapy regimes may limit bone loss. Aggressive treatment in early disease has also been shown to limit disease progression w17x and reduce bone

4 1050 A. L. Dolan et al. turnover w18x, however, such early studies inevitably include patients with a naturally good prognosis. It is encouraging to see DMARDs alone can limit bone loss even in those with established disease and gives further support to the current strategy of changing DMARD to optimise disease control. The study design did not allow comparison with a group of patients given placebo for ethical reasons and hence it was not possible to follow the natural progression of bone turnover and bone density if treatment was not given. This study is relatively small and was performed during the course of routine follow-up of patients in a clinic; hence there was not complete serial BMD data for all those originally enrolled. A power calculation suggests that the failure to show a change in BMD in the 21 patients with all three serial scans is a valid conclusion rather than a type 2 error. However, there is a potential selection bias in that those failing to attend for all scans may be generally less compliant in other aspects of treatment and as such have a poorer prognosis. A larger study to address the issues raised in this clinical study would be warranted. Disease activity is a significant determinant of bone turnover in active RA. Gough w10x showed patients with active disease and higher cumulative CRP had greater bone loss, in early RA. In common with previous studies, we have found that bone resorption is increased in active RA and that disease activity, as shown by ESR and the DAS, correlates with markers of bone resorption (D-PYR). The novel finding in this study, is that in both established and early RA, intervention with DMARDs alone can itself reduce bone resorption, as demonstrated by the fall in bone markers seen here. There is an inverse relationship between early suppression of disease activity and preservation of BMD. ESR, over the 1 yr after commencing the current DMARD was the most significant determinant of bone resorption (D-PYR), confirming the importance of the inflammatory state in bone loss. The HAQ, reflecting functional state, showed no relationship with bone resorption over time. The effect of DMARDs in reducing bone loss is apparent in the bone markers by 6 months on treatment, long before densitometry could be expected to demonstrate a change. The mechanism by which the inflammatory cytokines from active rheumatoid joints affects bone turnover has recently been studied. Inflamed RA synovium releases inflammatory cytokines, such as IL1 and IL6, which can exert their effects on bone locally and throughout the skeleton w19, 20x, possibly by acting via complex signalling pathways, such as the newly identified osteoprotegerin pathways w21x. In normal trabecular bone the remodelling cycle is stimulated by the production of IL6 from osteoblasts, which stimulate osteoclast maturation, bringing about bone resorption w22x. In diseases with high levels of systemic inflammatory cytokines, the normal bone remodelling cycle may be over-ridden or uncoupled and systemic IL6 acts directly on osteoblasts. This is the case in myeloma w23x and has been suggested in polymyalgia rheumatica w24x. Elevation of bone resorption markers (PYR) without elevation of formation markers, suggests bone resorption is the dominant process in RA w18x. Early change in D-PYR in the first 3 months of DMARDs was not related to spine BMD at 1 yr. Therefore, it is unlikely that this marker can be used as a surrogate to predict future bone density in individuals. However, the observed fall in bone resorption overall is compatible with the preservation of BMD seen in this group. It is possible that the changes in bone resorption markers indicate reductions in bone turnover, which may influence qualities of bone microarchitecture, which are not measured in a bone density scan w25x. Clinical studies with raloxifene w26x and nasal calcitonin w27x indicate that bone density is not the final arbiter of future fracture risk, as these treatments prevent future fracture to a much greater degree than would be predicted by their effect on BMD. The concept of bone quality and turnover may be as important. If DMARDs reduce bone turnover, that in itself may be adequate to reduce the future fracture risk. Further studies are needed to address this hypothesis. Acknowledgement This study was supported by a grant from the National Osteoporosis Society. References 1. Sambrook PN. The skeleton in rheumatoid arthritis: common mechanisms for bone erosion and osteoporosis? J Rheumatol 2000;27: Joffe I, Epstein S. Osteoporosis associated with rheumatoid arthritis: pathogenesis and management. Semin Arthritis Rheum 1991;20: Spector TD, Hall GM, McCloskey EV, Kanis JA. Risk of vertebral fracture in women with rheumatoid arthritis. Br Med J 1993;306: Scott DL. Clinical guidelines for management. Baillieres Clin Rheumatol 1997;11: Emery P. Assessment of rheumatoid arthritis a clinician s viewpoint. J Rheumatol (Suppl.) 1994;42: Garnero P, Delmas PD. New developments in biochemical markers for osteoporosis. Calcif Tissue Int 1996;59 (Suppl. 1):S Seibel MJ, Duncan A, Robins SP. Urinary hydroxypyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases. J Rheumatol 1989; 16: Spector TD, James IT, Hall GM, Thompson PW, Perrett D, Hart DJ. Increased levels of urinary collagen crosslinks in females with rheumatoid arthritis. Clin Rheumatol 1993;12: Gough AK, Peel NF, Eastell R, Holder RL, Lilley J, Emery P. Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis 1994;53: Gough AK, Lilley J, Eyre S, Holder RL, Emery P. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994;344:23 7.

5 Bone turnover in treated RA van der Heijde DM, van t Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20: Patel R, Blake GM, Rymer J, Fogelman I. Long-term precision of DXA scanning assessed over seven years in forty postmenopausal women. Osteoporos Int 2000; 11: Scott DL, Symmons DP, Coulton BL, Popert AJ. Longterm outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987;1: Proudman SM, Conaghan PG, Richardson C et al. Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 2000;43: Neva MH, Kauppi MJ, Kautiainen H et al. Combination drug therapy retards the development of rheumatoid atlantoaxial subluxations. FIN-RACo Trial Group. Arthritis Rheum 2000;43: Smolen JS, Kalden JR, Scott DL et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353: Emery P. Therapeutic approaches for early rheumatoid arthritis. How early? How aggressive? Br J Rheumatol 1995;34(Suppl. 2): Gough A, Sambrook P, Devlin J et al. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 1998; 25: Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988;2: Gowen M, Wood DD, Ihrie EJ, McGuire MK, Russell RG. An interleukin 1 like factor stimulates bone resorption in vitro. Nature 1983;306: Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15: Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995;332: Kawano M, Hirano T, Matsuda T et al. Autocrine generation and requirement of BSF-2uIL-6 for human multiple myelomas. Nature 1988;332: Dolan AL, Moniz C, Dasgupta B et al. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica. Arthritis Rheum 1997; 40: Riggs BL, Melton LJ 3rd. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 2002;17: Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE). J Am Med Assoc 1999; 282: Chesnut CH, Silverman S, Andriano K et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence Of Osteoporotic Fractures study. PROOF Study Group. Am J Med 2000;109:

Comparison of Bone Density of Distal Radius With Hip and Spine Using DXA

Comparison of Bone Density of Distal Radius With Hip and Spine Using DXA ORIGINAL ARTICLE Comparison of Bone Density of Distal Radius With Hip and Spine Using DXA Leila Amiri 1, Azita Kheiltash 2, Shafieh Movassaghi 1, Maryam Moghaddassi 1, and Leila Seddigh 2 1 Rheumatology

More information

8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview

8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview Disclosure Glucocorticoid induced osteoporosis: overlooked and undertreated? I have no financial disclosure relevant to this presentation Tasma Harindhanavudhi, MD Division of Diabetes and Endocrinology

More information

Concordance with the British Society of Rheumatology (BSR) 2010 recommendations on eligibility criteria for the first biologic agent

Concordance with the British Society of Rheumatology (BSR) 2010 recommendations on eligibility criteria for the first biologic agent Concordance with the British Society of Rheumatology (BSR) 2010 recommendations on eligibility criteria for the first biologic agent Michela Frendo, John Paul Caruana Galizia, Andrew A Borg Abstract Aims:

More information

Postmenopausal osteoporosis is a systemic

Postmenopausal osteoporosis is a systemic OSTEOPOROSIS: HARD FACTS ABOUT BONES Steven T. Harris, MD, FACP* ABSTRACT As a consequence of the aging process, osteoporosis affects all men and women. Agerelated loss of bone mass leads to skeletal fragility

More information

Fragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey

Fragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone

More information

Horizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329

Horizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329 Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature

More information

Index. Rheum Dis Clin N Am 32 (2006) Note: Page numbers of article titles are in boldface type.

Index. Rheum Dis Clin N Am 32 (2006) Note: Page numbers of article titles are in boldface type. Rheum Dis Clin N Am 32 (2006) 775 780 Index Note: Page numbers of article titles are in boldface type. A AACE (American Association of Clinical Endocrinologists), bone mineral density recommendations of,

More information

Osteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT

Osteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Osteoporosis update Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Outline Background BMD Tools for assessing fracture risk Case study Denosumab Treatment breaks BMD BMD predicts fracture risk but

More information

Bringing the clinical experience with anakinra to the patient

Bringing the clinical experience with anakinra to the patient Rheumatology 2003;42(Suppl. 2):ii36 ii40 doi:10.1093/rheumatology/keg331, available online at www.rheumatology.oupjournals.org Bringing the clinical experience with anakinra to the patient S. B. Cohen

More information

Skeletal Manifestations

Skeletal Manifestations Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes

More information

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS 4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending

More information

Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis

Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis Annals of the Rheumatic Diseases 1994; 53: 117-121 117 Rheumatology, Whipps Cross Hospital, Leytonstone, London, United S Donnelly D V Doyle A Denton I Rolfe Human Metabolism, University of Sheffield Medical

More information

Guideline for the investigation and management of osteoporosis. for hospitals and General Practice

Guideline for the investigation and management of osteoporosis. for hospitals and General Practice Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density

More information

European Journal of Endocrinology (1997) ISSN

European Journal of Endocrinology (1997) ISSN European Journal of Endocrinology (1997) 137 167 171 ISSN 0804-4643 Change in C-terminal cross-linking domain of type I collagen in urine, a new marker of bone resorption, during and after gonadotropin-releasing

More information

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,

More information

Submission to the National Institute for Clinical Excellence on

Submission to the National Institute for Clinical Excellence on Submission to the National Institute for Clinical Excellence on Strontium ranelate for the prevention of osteoporotic fractures in postmenopausal women with osteoporosis by The Society for Endocrinology

More information

Overview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence

Overview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence Overview Osteoporosis and Metabolic Bone Disease Dr Chandini Rao Consultant Rheumatologist Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases Bone Biology Osteoporosis Increased bone remodelling

More information

Oral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis

Oral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis Oral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis Miriam Silverberg A. Study Purpose and Rationale More than 70% of fractures in people after the age of

More information

What is Osteoporosis?

What is Osteoporosis? What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of

More information

Efficacy of Anakinra in Bone: Comparison to Other Biologics

Efficacy of Anakinra in Bone: Comparison to Other Biologics Advances In Therapy Volume 19 No. 1 January/February 2002 Efficacy of Anakinra in Bone: Comparison to Other Biologics Stephen A. Paget, M.D. Hospital for Special Surgery Department of Rheumatic Disease

More information

The Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD

The Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase

More information

AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT. Committee on Rheumatologic Care

AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT. Committee on Rheumatologic Care AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT SUBJECT: PRESENTED BY: FOR DISTRIBUTION TO: Bone Mineral Density Measurement and the Role of Rheumatologists in the Management of Osteoporosis Committee

More information

Osteoporosis. Overview

Osteoporosis. Overview v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)

More information

Collagen Crosslinks, Any Method

Collagen Crosslinks, Any Method 190.19 - Collagen Crosslinks, Any Method Collagen crosslinks, part of the matrix of bone upon which bone mineral is deposited, are biochemical markers the excretion of which provides a quantitative measurement

More information

Prophylactic treatment for osteoporosis: Student EBM Presentation

Prophylactic treatment for osteoporosis: Student EBM Presentation Prophylactic treatment for osteoporosis: Student EBM Presentation Callum Harris & Ealish Swift University of Oxford October 2015 Example patient JS is a 67 year old lady who needs to start taking long-term

More information

Osteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK

Osteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK Journal of Medical Sciences (2010); 3(3): 00-00 Review Article Osteoporosis Open Access John A. Kanis WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK incorporated into

More information

BONE REMODELLING. Tim Arnett. University College London. Department of Anatomy and Developmental Biology

BONE REMODELLING. Tim Arnett. University College London. Department of Anatomy and Developmental Biology BONE REMODELLING Tim Arnett Department of Anatomy and Developmental Biology University College London The skeleton, out of sight and often out of mind, is a formidable mass of tissue occupying about 9%

More information

Collagen Crosslinks, Any Method

Collagen Crosslinks, Any Method 190.19 - Collagen Crosslinks, Any Method Collagen crosslinks, part of the matrix of bone upon which bone mineral is deposited, are biochemical markers the excretion of which provides a quantitative measurement

More information

ORIGINAL INVESTIGATION. Vertebral Fracture Risk With Long-term Corticosteroid Therapy

ORIGINAL INVESTIGATION. Vertebral Fracture Risk With Long-term Corticosteroid Therapy ORIGINAL INVESTIGATION Vertebral Fracture Risk With Long-term Corticosteroid Therapy Prevalence and Relation to Age, Bone Density, and Corticosteroid Use Vasi Naganathan, FRACP; Graeme Jones, FRACP, MD;

More information

International Journal of Health Sciences and Research ISSN:

International Journal of Health Sciences and Research  ISSN: International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Osteoporosis- Do We Need to Think Beyond Bone Mineral Density? Dr Preeti Soni 1, Dr Shipra

More information

Etiology: Pathogenesis Clinical manifestation Investigation Treatment Prognosis

Etiology: Pathogenesis Clinical manifestation Investigation Treatment Prognosis Etiology: Pathogenesis Clinical manifestation Investigation Treatment Prognosis JIA is the most common rheumatic disease in childhood and a major cause of chronic disability. Etiology: Unknown, but may

More information

The relationship between soft tissue swelling, joint space narrowing and erosive damage in hand X-rays of patients with rheumatoid arthritis

The relationship between soft tissue swelling, joint space narrowing and erosive damage in hand X-rays of patients with rheumatoid arthritis Rheumatology 2001;40:297±301 The relationship between soft tissue swelling, joint space narrowing and erosive damage in hand X-rays of patients with rheumatoid arthritis J. Kirwan, M. Byron and I. Watt

More information

Dumfries and Galloway. Treatment Protocol for Osteoporosis

Dumfries and Galloway. Treatment Protocol for Osteoporosis Dumfries and Galloway Treatment Protocol for Osteoporosis DIAGNOSIS OF OSTEOPOROSIS 2 Diagnostic Criteria 2 REFERRAL CRITERIA FOR DEXA 3 TREATMENT 4 Non-Drug Therapy : for all 4 Non-Drug Therapy : in the

More information

Osteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis

Osteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health

More information

Osteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.

Osteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved

More information

Objectives. Discuss bone health and the consequences of osteoporosis on patients medical and disability status.

Objectives. Discuss bone health and the consequences of osteoporosis on patients medical and disability status. Objectives Discuss bone health and the consequences of osteoporosis on patients medical and disability status. Discuss the pathophysiology of osteoporosis and major risk factors. Assess the major diagnostic

More information

DEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN

DEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN October 2-4, Liverpool, UK EURO SPINE 2013 DEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN D. Colangelo, L. A. Nasto, M. Mormando, E.

More information

OSTEOPOROSIS MANAGEMENT AND INVESTIGATION. David A. Hanley, MD, FRCPC

OSTEOPOROSIS MANAGEMENT AND INVESTIGATION. David A. Hanley, MD, FRCPC OSTEOPOROSIS MANAGEMENT AND INVESTIGATION David A. Hanley, MD, FRCPC There is a huge care gap in the management of osteoporosis in this country. As yet unpublished findings from the Canadian Multicentre

More information

Are glucocorticoid-induced osteoporosis recommendations sufficient to determine antiosteoporotic treatment for patients with rheumatoid arthritis?

Are glucocorticoid-induced osteoporosis recommendations sufficient to determine antiosteoporotic treatment for patients with rheumatoid arthritis? ORIGINAL ARTICLE Korean J Intern Med 2014;29:509-515 Are glucocorticoid-induced osteoporosis recommendations sufficient to determine antiosteoporotic treatment for patients with rheumatoid arthritis? Joo-Hyun

More information

Introduction ORIGINAL ARTICLE

Introduction ORIGINAL ARTICLE Mod Rheumatol (2007) 17:28 32 Japan College of Rheumatology 2007 DOI 10.1007/s10165-006-0532-0 ORIGINAL ARTICLE Hisashi Yamanaka Yoshiya Tanaka Naoya Sekiguchi Eisuke Inoue Kazuyoshi Saito Hideto Kameda

More information

Interpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm

Interpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis

More information

Bone Turnover Markers for the Diagnosis and Management of Osteoporosis and Diseases Associated with High Bone Turnover. Original Policy Date

Bone Turnover Markers for the Diagnosis and Management of Osteoporosis and Diseases Associated with High Bone Turnover. Original Policy Date MP 2.04.10 Bone Turnover Markers for the Diagnosis and Management of Osteoporosis and Diseases Associated with High Bone Turnover Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013

More information

Center for Rheumatology, Maxima Medical Center Eindhoven, The Netherlands; 4

Center for Rheumatology, Maxima Medical Center Eindhoven, The Netherlands; 4 High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis-trial

More information

Presenter: 翁家嫻 Venue date:

Presenter: 翁家嫻 Venue date: FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURES 1 Presenter: 翁家嫻 Venue date: 2018.03.13 PMO: postmenopausal osteoporosis. 1. Prolia (denosumab), Summary of Product

More information

Clinician s Guide to Prevention and Treatment of Osteoporosis

Clinician s Guide to Prevention and Treatment of Osteoporosis Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening

More information

Osteoporosis Clinical Guideline. Rheumatology January 2017

Osteoporosis Clinical Guideline. Rheumatology January 2017 Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis

More information

Disclosure and Conflicts of Interest Steven T Harris MD Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis

Disclosure and Conflicts of Interest Steven T Harris MD Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis Steven T Harris MD FACP Clinical Professor of Medicine University of California, San Francisco Disclosure and Conflicts of Interest

More information

BMD: A Continuum of Risk WHO Bone Density Criteria

BMD: A Continuum of Risk WHO Bone Density Criteria Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris

More information

Ankylosing spondylitis (AS) is characterized by inflammation

Ankylosing spondylitis (AS) is characterized by inflammation ORIGINAL ARTICLE Is Osteoporosis Generalized or Localized to Central Skeleton in Ankylosing Spondylitis? Selda Sarikaya, MD, Aynur Basaran, MD, Yasin Tekin, MD, Senay Ozdolap, MD, and Ozgur Ortancil, MD

More information

Nutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio

Nutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio Osteoporosis 1 Nutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio 1) Objectives: a) To understand bone growth and development

More information

Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases

Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab

More information

Download slides:

Download slides: Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division

More information

Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC

Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with

More information

Relationship between bone resorption and adrenal sex steroids and their derivatives in oophorectomized women

Relationship between bone resorption and adrenal sex steroids and their derivatives in oophorectomized women FERTILITY AND STERILITY VOL. 82, NO. 6, DECEMBER 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Relationship between bone

More information

Annual Rheumatology & Therapeutics Review for Organizations & Societies

Annual Rheumatology & Therapeutics Review for Organizations & Societies Annual Rheumatology & Therapeutics Review for Organizations & Societies Biochemical Markers of Bone Turnover: Definitions and Recommendations for Monitoring Therapy Learning Objectives for Biochemical

More information

LOCALLY AVAILABLE BIOLOGIC AGENTS IN THE TREATMENT OF PSORIATIC ARTHRITIS

LOCALLY AVAILABLE BIOLOGIC AGENTS IN THE TREATMENT OF PSORIATIC ARTHRITIS Locally Available Biologic Agents in the Treatment of Psoriatic Arthritis 253 Phil. J. Internal Medicine, 47: 253-259, Nov.-Dec., 2009 LOCALLY AVAILABLE BIOLOGIC AGENTS IN THE TREATMENT OF PSORIATIC ARTHRITIS

More information

Current and Emerging Strategies for Osteoporosis

Current and Emerging Strategies for Osteoporosis Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis

More information

Relative effect (95% CI) RR LOW 2,3 due to indirectness, imprecision. RR 1.45 (0.43 to 4.84) due to indirectness, imprecision. (0.18 to 20.

Relative effect (95% CI) RR LOW 2,3 due to indirectness, imprecision. RR 1.45 (0.43 to 4.84) due to indirectness, imprecision. (0.18 to 20. Appendix: Evidence Reports Question In patients with early RA with moderate or high disease activity, who are DMARD-naive, what is the impact of combination double DMARD therapy vs. mono-dmard therapy

More information

Preliminary Communication

Preliminary Communication Preliminary Communication Prevention of glucocorticoid-induced osteoporosis: a re audit of dual-energy x-ray absorptiometry scan access and management guideline compliance Aim: To evaluate the current

More information

Recombinant PTH: A Study of the Outcome of Teriparatide Therapy for 138 Patients with Osteoporosis

Recombinant PTH: A Study of the Outcome of Teriparatide Therapy for 138 Patients with Osteoporosis Ulster Med J 2013;82(2):89-93 Paper Recombinant PTH: A Study of the Outcome of Teriparatide Therapy for 138 Patients with Osteoporosis Thomas McNeilly, Colette McNally, Michael Finch, Timothy Beringer

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency London, 20 January 2010 Doc. Ref. EMA/CHMP/EWP/15912/2010 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CONCEPT PAPER ON THE NEED FOR AN ADDENDUM ON THE CLINICAL INVESTIGATION

More information

O. Bruyère M. Fossi B. Zegels L. Leonori M. Hiligsmann A. Neuprez J.-Y. Reginster

O. Bruyère M. Fossi B. Zegels L. Leonori M. Hiligsmann A. Neuprez J.-Y. Reginster DOI 10.1007/s00296-012-2460-y ORIGINAL ARTICLE Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security

More information

Calcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD

Calcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:

More information

Osteoporosis - recent advances in diagnosis and treatment

Osteoporosis - recent advances in diagnosis and treatment Title Osteoporosis - recent advances in diagnosis and treatment Author(s) Kung, AWC Citation The 4th Medical Research Conference (MRC 1999), Hong Kong, China, 30-31 January 1999. In Hong Kong Practitioner,

More information

Osteoporosis/Fracture Prevention

Osteoporosis/Fracture Prevention Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team

More information

Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis

Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis Rheumatology 2003;42:83 88 doi:10.1093/rheumatology/keg037, available online at www.rheumatology.oupjournals.org Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis M.J.Green,A.K.S.Gough,J.Devlin,J.Smith,P.Astin,

More information

Osteoporosis. Treatment of a Silently Developing Disease

Osteoporosis. Treatment of a Silently Developing Disease Osteoporosis Treatment of a Silently Developing Disease Marc K. Drezner, MD Senior Associate Dean Emeritus Professor of Medicine Emeritus University of Wisconsin-Madison Auditorium The Forest at Duke October

More information

Correlation between Thyroid Function and Bone Mineral Density in Elderly People

Correlation between Thyroid Function and Bone Mineral Density in Elderly People IBBJ Spring 2016, Vol 2, No 2 Original Article Correlation between Thyroid Function and Bone Mineral Density in Elderly People Ali Mirzapour 1, Fatemeh Shahnavazi 2, Ahmad Karkhah 3, Seyed Reza Hosseini

More information

Bone mineral density and bone turnover in spinal

Bone mineral density and bone turnover in spinal Annals ofthe Rheumatc Diseases 1995; 54: 867-871 867 EXTENDED REPORTS Department of Human Metabolism and Clinical Biochemistry, University of Sheffield, Northern General Hospital, Sheffield, United Kingdom

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage

More information

Horizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre

Horizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information

More information

Horizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330

Horizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises

More information

Name of Policy: Zoledronic Acid (Reclast ) Injection

Name of Policy: Zoledronic Acid (Reclast ) Injection Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and

More information

This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against

This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against Juliet Compston Professor of Bone Medicine University of Cambridge School of Clinical

More information

TREATMENT OF OSTEOPOROSIS

TREATMENT OF OSTEOPOROSIS TREATMENT OF OSTEOPOROSIS Summary Prevention is the key issue in the management of osteoporosis. HRT is the agent of choice for prevention of postmenopausal osteoporosis. Bisphosphonates and Calcitonin

More information

I mmunosuppressive pulse treatment with intravenous

I mmunosuppressive pulse treatment with intravenous 940 EXTENDED REPORT Bone loss in patients treated with pulses of methylprednisolone is not negligible: a short term prospective observational study G Haugeberg, B Griffiths, K B Sokoll, P Emery... See

More information

Page: 1 of 12. Bone Turnover Markers for Diagnosis and Management of Osteoporosis and Diseases Associated With High Bone Turnover

Page: 1 of 12. Bone Turnover Markers for Diagnosis and Management of Osteoporosis and Diseases Associated With High Bone Turnover Last Review Status/Date: December 2014 Page: 1 of 12 Management of Osteoporosis and Diseases Description Bone turnover markers are biochemical markers of either bone formation or bone resorption. Commercially

More information

Treat - to - Target Pathway Commissioning Chronic and Complex Care MIDLANDS RHEUMATOLOGY & MUSCULOSKELETAL (MSK) COMMISSIONING NETWORK

Treat - to - Target Pathway Commissioning Chronic and Complex Care MIDLANDS RHEUMATOLOGY & MUSCULOSKELETAL (MSK) COMMISSIONING NETWORK Treat - to - Target Pathway Commissioning Chronic and Complex Care MIDLANDS RHEUMATOLOGY & MUSCULOSKELETAL (MSK) COMMISSIONING NETWORK Dr Bruce Kirkham Consultant Rheumatologist Guy s & St Thomas NHS Foundation

More information

Osteoporosis challenges

Osteoporosis challenges Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1

More information

SCHEDULE 2 THE SERVICES. A. Service Specifications

SCHEDULE 2 THE SERVICES. A. Service Specifications SCHEDULE 2 THE SERVICES A. Service Specifications Service Specification No. 04/MSKT/0013 Service PAN DORSET FRACTURE LIAISON SERVICE Commissioner Lead CCP for Musculoskeletal & Trauma Provider Lead Deputy

More information

Study of Bone Mineral Density (BMD) in Patients with Rheumatoid Arthritis and its Corelation with Severity of the Disease

Study of Bone Mineral Density (BMD) in Patients with Rheumatoid Arthritis and its Corelation with Severity of the Disease 26 ORIGINAL ARTICLE Study of Bone Mineral Density (BMD) in Patients with Rheumatoid Arthritis and its Corelation with Severity of the Disease Liyakat Ali Gauri 1, Qadir Fatima 2, Sharanbasu Diggi 3, Asim

More information

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study Rheumatol Int (2006) 26: 427 431 DOI 10.1007/s00296-005-0004-4 ORIGINAL ARTICLE J. D. Ringe Æ H. Faber Æ P. Farahmand Æ A. Dorst Efficacy of risedronate in men with primary and secondary osteoporosis:

More information

Based on review of available data, the Company may consider the use of denosumab (Prolia) for the

Based on review of available data, the Company may consider the use of denosumab (Prolia) for the Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

denosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017

denosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017 Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

John J. Wolf, DO Family Medicine

John J. Wolf, DO Family Medicine John J. Wolf, DO Family Medicine Objectives: 1. Review incidence & Risk of Osteoporosis 2.Review indications for testing 3.Review current pharmacologic & Non pharmacologic Tx options 4.Understand & Utilize

More information

Using the FRAX Tool. Osteoporosis Definition

Using the FRAX Tool. Osteoporosis Definition How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX

More information

Rheumatoid arthritis

Rheumatoid arthritis Rheumatoid arthritis 1 Definition Rheumatoid arthritis is one of the most common inflammatory disorders affecting the population worldwide. It is a systemic inflammatory disease which affects not only

More information

Coordinator of Post Professional Programs Texas Woman's University 1

Coordinator of Post Professional Programs Texas Woman's University 1 OSTEOPOROSIS Update 2007-2008 April 26, 2008 How much of our BMD is under our control (vs. genetics)? 1 2 Genetic effects on bone loss: longitudinal twin study (Makovey, 2007) Peak BMD is under genetic

More information

Osteoporosis is estimated to develop in 1 out of 4 women over the age of 50. Influence of bone densitometry results on the treatment of osteoporosis

Osteoporosis is estimated to develop in 1 out of 4 women over the age of 50. Influence of bone densitometry results on the treatment of osteoporosis Influence of bone densitometry results on the treatment of osteoporosis Nicole S. Fitt, * Susan L. Mitchell, * Ann Cranney, Karen Gulenchyn, Max Huang, * Peter Tugwell Abstract Background: Measurement

More information

OSTEOPOROSIS: PREVENTION AND MANAGEMENT

OSTEOPOROSIS: PREVENTION AND MANAGEMENT OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring

More information

Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.

Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Appendix I - Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective

More information

Osteoporosis: Not Just for Women Anymore. Osteoporosis is characterized by low bone. By Lisanne G. Laurier, MD, PhD, FRCPC.

Osteoporosis: Not Just for Women Anymore. Osteoporosis is characterized by low bone. By Lisanne G. Laurier, MD, PhD, FRCPC. Focus on CME at the University of Western Ontario Osteoporosis: Not Just for Women Anymore By Lisanne G. Laurier, MD, PhD, FRCPC Osteoporosis is characterized by low bone mass and microarchitectural deterioration

More information

AN APPROACH TO THE PATIENT WITH OSTEOPOROSIS. Malik Mumtaz

AN APPROACH TO THE PATIENT WITH OSTEOPOROSIS. Malik Mumtaz Malaysian Journal of Medical Sciences, Vol. 8, No. 1, Januari 2001 (11-19) BRIEF ARTICLE Department of Medicine School of Medical Sciences, Universiti Sains Malaysia 16150 Kubang Kerian, Kelantan, Malaysia

More information

Immunological Aspect of Ozone in Rheumatic Diseases

Immunological Aspect of Ozone in Rheumatic Diseases Immunological Aspect of Ozone in Rheumatic Diseases Prof. Dr. med. Z. Fahmy Chief Consulting Rheumatologist Augusta Clinic for Rheumatic Diseases And Rehabilitation Bad Kreuznach Germany Rheumatoid arthritis

More information

Orthopantomogram as an effective tool for the diagnosis of osteoporosis-a study

Orthopantomogram as an effective tool for the diagnosis of osteoporosis-a study Original Research Article Comparative Study of Mandibular Cortical Index in Orthopantomogram and Bone Mineral Density of Lumbar Vertebrae in Dual Energy X-Ray Absorptiometry in Postmenopausal Females in

More information

Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015. Dr.

Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015. Dr. Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015 Dr. Tessem Osteoporosis is a public health problem in all stages of life. Many

More information

Drug Intervals (Holidays) with Oral Bisphosphonates

Drug Intervals (Holidays) with Oral Bisphosphonates Drug Intervals (Holidays) with Oral Bisphosphonates Rizwan Rajak Consultant Rheumatologist & Lead for Osteoporosis GP Postgraduate Meeting April 2018 Contents Case presentation Pathway for Bisphosphonate

More information

An Update on Osteoporosis Treatments

An Update on Osteoporosis Treatments An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and

More information

Assessment and Treatment of Osteoporosis Professor T.Masud

Assessment and Treatment of Osteoporosis Professor T.Masud Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis

More information

Osteoporosis Update. Greg Summers Consultant Rheumatologist

Osteoporosis Update. Greg Summers Consultant Rheumatologist Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o

More information